Genetic alterations in the Ras/Raf/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma

Cancer

Volumn 116, Issue 12, 2010, Pages 2974-2983

  Santarpia, Libero ^a,c   Myers, Jeffrey N ^a   Sherman, Steven I ^a   Trimarchi, Francesco ^b   Clayman, Gary L ^a   El Naggar, Adel K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MESSINA   (Italy)

^c Hospital of Prato and Istituto Toscana Tumori   (Italy)

Author keywords

Follicular variant papillary thyroid cancer; Genetic alterations; Mitogen activated protein kinase pathway; PAX8 PPAR translocations; Phosphatidylinositol 3 kinase pathway; Phosphorylation activation; RET PTC rearrangements

Indexed keywords

B RAF KINASE; GLUTAMATE ACETYLTRANSFERASE; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CATALYTIC PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT ALPHA; PROTEIN KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; VALINE;

ARTICLE; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; GENE ACTIVATION; GENE IDENTIFICATION; GENE MUTATION; GENE TRANSFER; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; PAPILLARY THYROID CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA, PAPILLARY, FOLLICULAR; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 77954022714     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25061     Document Type: Article

References (44)

1. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318-2326.
2. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:213-220. (Pubitemid 43069140)
3. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13:1161-1170.
4. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008;93:278-284.
5. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and PI3K/Akt and MAP kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93:3106-3116.
6. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D. In vitro reconstruction of tumour initiation in a human epithelium. Oncogene. 1994;9:281-290.
7. Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G, Fagin JA. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J Biol Chem. 2006;281:3800-3809. (Pubitemid 43847804)
8. Lemoine NR, Mayall ES, Wyllie FS, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988;48:4459-4463.
9. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88:2745-2752. (Pubitemid 36724451)
10. Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21:3226-3235. (Pubitemid 46606254)
11. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742-762. (Pubitemid 350294294)
12. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol. 2009;40:827-833.
13. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004;202:247-251.
14. Barzon L, Masi G, Merante Boschin I, et al. Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Eur J Endocrinol. 2008;159:77-80. (Pubitemid 351969134)
15. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085-4090. (Pubitemid 350074715)
16. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol. 2006;155:645-653.
17. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(suppl 2):S37-S43. (Pubitemid 351592770)
18. Cheung L, Messina M, Gill A, et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2003;88:354-357.
19. Sahin M, Allard BL, Yates M, et al. PPARγ staining as a surrogate for PAX8/PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab. 2005;90:463-468.
20. Placzkowski KA, Reddi HV, Grebe SK, Eberhardt NL, McIver B. The role of the PAX8/PPARgamma fusion oncogene in thyroid cancer. PPAR Res. 2008;2008:672829-672829.
21. Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am. 2008;37:375-387, viii-ix.
22. Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Semin Oncol. 2007;34:428-434.
23. Shinohara M, Chung YJ, Saji M, Ringel MD. AKT in thyroid tumorigenesis and progression. Endocrinology. 2007;148:942-947.
24. Wang Y, Hou P, Yu H, et al. High prevalence and mutual exclusivity of genetic alterations in the PI3K/Akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007;92:2387-2390.
25. Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2008;93:611-618. (Pubitemid 351240838)
26. Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65:10199-10207. (Pubitemid 41743711)
27. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885-4893.
28. Li Volsi, Albores-Saavedra J, Asa SL, et al. Papillary carcinoma. In: DeLellis LA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumors of the Endocrine Organs. World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2004:57-72.
29. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26:1016-1023.
30. Nakazawa T, Kondo T, Kobayashi Y, et al. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan). Cancer. 2005;104:943-951. (Pubitemid 41170221)
31. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer. 2008;98:1533-1535.
32. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22. (Pubitemid 37328883)
33. Di Cristofaro J, Marcy M, Vasko V, et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol. 2006;37:824-830. (Pubitemid 43902941)
34. Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94:4735-4741.
35. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer. 2009;115:972-980.
36. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 2005;115:1068-1081.
37. Hennige AM, Lammers R, Arlt D, et al. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells. Mol Cell Endocrinol. 2000;167:69-76.
38. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem. 2000;275:3568-3576. (Pubitemid 30083066)
39. Miyagi E, Braga-Basaria M, Hardy E, et al. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog. 2004;41:98-107. (Pubitemid 39336759)
40. van Weering DH, de Rooij J, Marte B, Downward J, Bos JL, Burgering BM. Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous Ras. Mol Cell Biol. 1998;18:1802-1811. (Pubitemid 28152629)
41. De Vita G, Melillo RM, Carlomagno F, et al. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res. 2000;60:3727-3731. (Pubitemid 32204559)
42. Pelicci G, Troglio F, Bodini A, et al. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol. 2002;22:7351-7363.
43. De Falco V, Guarino V, Malorni L, et al. RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors. Oncogene. 2005;24:6303-6313. (Pubitemid 43080053)
44. Lodyga M, De Falco V, Bai XH, et al. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene. 2009;28:937-949.